Catalyst Cascade Reactions in One Flow within a Compartmentalized Green Solve...
Catalyst Cascade Reactions in One Flow within a Compartmentalized Green Solvent Digital Synthesis Machinery End to End Green Process Design for Pharmaceuticals
"ONE-FLOW translates ‘vertical hierarchy’ of chemical multistep synthesis with its complex machinery into self-organising ‘horizontal hierarchy’ of a compartmentalized flow reactor system – a biomimetic digital flow cascade machin...
"ONE-FLOW translates ‘vertical hierarchy’ of chemical multistep synthesis with its complex machinery into self-organising ‘horizontal hierarchy’ of a compartmentalized flow reactor system – a biomimetic digital flow cascade machinery with just one reactor passage. To keep horizontal hierarchy manageable, orthogonality among the consecutive reactions needs to be increased. The winning point of nature is to have invented catalytic cascades. ONE-FLOW will uplift that by enabling the best bio- and chemocatalysts working hand in hand. 4 synthetic flow cascades ('metabolic pathways’) and 1 flow cascade driven by automated intelligence ('signaling pathway') will produce 4 Top-list 2020 drugs. ‘The Compartmentalized Smart Factory’ will develop organic, inorganic, and mechanical compartmentalization. ‘The Green-Solvent Spaciant Factory’ will fluidically allow the use of interim reaction spaces (spaciants). ‘The Systemic Operations Factory’ will aim at full orthogonality using data-base guided ultimate process harmonization. ‘The Digital Machine-to-Machine Factory’ will alter the landscape of chemical synthesis by virtue of the ""Internet of Chemical Things"". Automated machine-to-machine data transfer enables relegation of process monitoring to central computer systems under the oversight of chemists. ‘The Fully Continuous Integrated Factory’ will develop a commercial platform technology under the auspices of sustainability-driven process-design evaluation, making amenable the new kind of processing to all chemists. ONE-FLOW has massive impact potential: i) 38 billion Euro production cost saving; ii) 300 million EUR cost saving per drug; iii) address diseases with 500 billion Euro medication costs; iv) increase market share of emerging high-tech SME players by 10% in 10 years; v) open new windows of opportunity (personalized medicine) with 200-500 million Euro per disease; and vi) achieve 40% female share on a senior scientist level (ONE-FLOW: 34% senior, 57% junior)."ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.